nach oben

01.12.2021 | Research | Ausgabe 1/2021 Open Access

Association of three missense mutations in the homocysteine-related MTHFR and MTRR gene with risk of polycystic ovary syndrome in Southern Chinese women

Zeitschrift:: Reproductive Biology and Endocrinology > Ausgabe 1/2021

Autoren:: Wanqin Feng, Yan Zhang, Yuan Pan, Yi Zhang, Minjuan Liu, Yuxin Huang, Yuanling Xiao, Wenyu Mo, Junjie Jiao, Xiaoyang Wang, Dan Tian, Lixia Yang, Ying Ma

» Zur Zusammenfassung PDF-Version jetzt herunterladen

Wichtige Hinweise

Wanqin Feng and Yan Zhang contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abbreviations

PCOS

Polycystic ovary syndrome

MTHFR

Methylene tetrahydrofolate reductase

MTRR

Methionine synthase reductase

SNPs

Single nucleotide polymorphisms

Background

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disease that affects women of childbearing age. There is no cure for PCOS and it is prone to relapse [ 1– 3]. Although the etiology of PCOS is not yet completely understood, increasing evidence suggests that it is a multifactorial disease caused by environmental and genetic factors [ 4– 7]. Environmental factors include environmental toxins, diet and nutrition, socioeconomic status, and geography, which are believed to affect the pathogenesis of PCOS [ 8– 10]. Moreover, mutations, polymorphisms, and differential regulation of genes may contribute to the genetic pathogenesis of PCOS [ 11, 12]. While a limited number of studies have reported relationships between PCOS and several candidate genes [ 13– 15], no single gene has yet been identified as a biomarker.

Several studies have shown that an elevated homocysteine level may be related to the pathogenesis of PCOS [ 16– 20]. A previous study found that elevated homocysteine levels could modulate M2 macrophage polarization via estrogen suppression, which promoted insulin resistance and adipose tissue inflammation in PCOS mice [ 20]. A multi-center, randomized, controlled trial with 936 participants showed that hyperhomocysteinemia, a medical condition characterized by an abnormally high level of homocysteine in the blood, increased the risk of pregnancy loss and reduced ovulation in people with PCOS [ 16].

In humans, the level of homocysteine is mainly affected by the metabolism of folic acid and methionine [ 21], where methylene tetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) are the key enzymes [ 22– 25]. Studies have shown that the activity of these two enzymes is mainly affected by three missense mutations, namely C677T ( MTHFR), A1298C ( MTHFR), and A66G ( MTRR) [ 23, 26, 27]. The C677T mutation is the substitution of base C at the 677 site with T, leading to the substitution of alanine with valine, which results in a thermolabile variant with reduced activity. The mutation of MTHFR A1298C is the substitution of base A to C at the 1298 site, leading to the substitution of glutamic acid with alanine, which reduces enzyme activity. The MTRR A66G mutation alters isoleucine into a methionine residue in the protein chain and subsequently disrupts the methionine/homocysteine cycle.

Therefore, we hypothesize that C677T, A1298C, and A66G may be risk factors for PCOS, acting through an increased level of homocysteine. In this case-control study, we performed a genotype analysis for the three missense mutations to elucidate if they were risk factors for PCOS. Furthermore, we examined whether the three mutations exerted their effect in PCOS by affecting the homocysteine level.

Materials and methods

Participants

This study recruited 150 premenopausal women with PCOS from the Department of Gynecology and Obstetrics, Zhujiang Hospital of the Southern Medical University (Guangzhou, PR China), between December 2018 and August 2019. All cases had a definitive diagnosis of PCOS, as per the Rotterdam diagnostic criteria [ 28]. A total of 300 age-matched, healthy, child-bearing women without PCOS were recruited as the control group for the same period. All cases and controls had no history of cancer, diabetes, hypertension, hyperprolactinemia, Cushing’s syndrome, acromegaly, immune system disorders, a recent history of pregnancy, oral contraceptive pill for half a year prior to the study, and no previous treatment with folic acid.

Written informed consent for the study was provided by each participant. Ethical approval for the study was granted by the Institutional Research Ethics Committee of Zhujiang Hospital of Southern Medical University.

Measures

In this study, two fasting venous blood samples were extracted from each subject. One was collected in a normal EP tube for serum measurements, and the other was collected in an anticoagulant-treated EP tube for DNA extraction. Both were stored at − 80℃ until use.

Serum measurements

Serum homocysteine levels were quantified using a cycling enzymatic method on a Mindray BS2000M automatic biochemical analyzer (Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, PR China). The detection limit was determined by analyzing 6 replicates of the zero calibrators and 2 replicates of the lowest nonzero calibrator. If the concentration of homocysteine was more than 50 µmol/L, the sample was manually diluted and retested. The reference range was 5–15 µmol/L.

DNA extraction and genotyping

The DNA samples were extracted by using Magnetic Blood Genomic DNA Kit (Tiangen biochemical Technology co., Beijing, China), and were stored at -20 °C until use.

Each DNA sample was assessed for MTRR A66G, MTHFR A1298C, and MTHFR C677T single nucleotide polymorphisms (SNPs) using the TaqMan-MGB SNPs Genotyping Assay (Applied Bio-systems Inc., Foster City, CA, USA). Fluorescence quantitative PCR was performed for TaqMan-MGB. The reagents and primers used were all from the Human MTHFR and MTRR Gene Polymorphism Detection Kit (Fluorescence PCR; SurExam Bio-Tech Co., Ltd, Guangzhou, PR China). The PCR amplification conditions were as follows: 95 °C denaturation for 10 min followed by 20 cycles of amplification (92 °C for 15 s and 60 °C for 60 s) and 35 cycles of amplification (89 °C for 15 s and 60 °C for 90 s). All assays were replicated twice and the genotype allocation was determined by an automatic allele calling the quality value of 0.95.

Statistical analysis

The differences in demographic and clinical characteristics were compared using the Chi-squared test or t-test. The deviation of genotype distribution was tested for Hardy–Weinberg equilibrium using the χ ² test. The associations between MTHFR/MTRR mutations and the risk of PCOS were assessed using logistic regression analyses under additive, dominant, and recessive models. Bonferroni correction was used to adjust for multiple comparisons. Linear regression was used to assess the associations between homocysteine and MTHFR/MTRR gene mutations. We further conducted a causal mediation analysis to test whether the association significance between MTHFR/MTRR mutations and PCOS was mediated via homocysteine level. Significance of the mediation effect was conducted using 5000 bootstrapped iterations mean indirect and direct effect. The bootstrapping test was performed using the SPSS PROCESS macro to test the statistical significance of the mediating effect [ 29].

For all multivariable models, potential confounders, including age, BMI, history of smoking, drinking, and hypertensive family history were adjusted. A two-tailed P-value of < 0.05 was considered statistically significant. The SPSS 19.0 statistical package was used for all data analyses.

Results

Participant characteristics

Table 1 shows the characteristics of the participants. The mean age of the PCOS group was 27.02 ± 4.76 years, which was not significantly different from that of the control group ( p = 0.363). Consistent with previous meta-analysis [ 30], the percentage of overweight or obesity in PCOS group is higher than the control group. The PCOS group subjects had a significantly lower folate level and higher homocysteine level compared to the control subjects. For the other characteristics, there was no significant difference between participants in the two groups.

Table 1

Demographic and clinical characteristics of the participants

Characteristics	Control group ( n = 300)	PCOS group ( n = 150)	P value
Age (years), mean ± SD	27.44 ± 4.21	27.02 ± 4.76	0.363
Height (m), mean ± SD	1.60 ± 0.03	1.60 ± 0.04	0.994
Body mass index (Kg/m ²), mean ± SD	20.31 ± 2.03	20.72 ± 3.01	0.131
Overweight or Obesity, n (%)	17 (5.7%)	17 (11.3%)	0.032
Smoking, n (%)	7 (2.3%)	5 (3.3%)	0.756
Drink, n (%)	6 (2.0%)	4 (2.7%)	0.910
Hypertensive family history, n (%)	13 (4.3%)	8 (5.3%)	0.635
Estradiol (pmol/L), median (IQR)	171.00 (135.5–218.75)	141.50 (98.75–206.25)	0.856
Prolactin (ug/L), median (IQR)	15.04 (8.52–20.58)	15.84 (10.99–25.18)	0.385
Testosterone (ug/L), median (IQR)	0.49 (0.42–0.53)	0.54 (0.44–0.68)	0.315
Follicle-stimulating hormone (IU/L, median (IQR)	8.05 (6.45–13.55)	7.05 (5.95–7.93)	0.102
Luteinizing hormone (IU/L), median (IQR)	4.54 (3.75–9.96)	5.67 (4.05–7.66)	0.554
Cholesterol (mmol/L), median (IQR)	4.66 (3.77–5.02)	4.37 (3.87–4.79)	0.157
Triglyceride (mmol/L), median (IQR)	0.84 (0.63–1.41)	0.82 (0.64–1.13)	0.561
Fasting glucose (mg/dl), median (IQR)	4.73 (4.62–5.22)	4.99 (4.81–5.24)	0.116
Fasting insulin (µU/ml), median (IQR)	5.76 (3.71–8.07)	5.24 (3.62–8.19)	0.514
Folate (ng/mL), mean ± SD	11.99 ± 2.58	10.49 ± 3.83	< 0.001
Homocysteine (µmol/L), mean ± SD	8.13 ± 1.21	10.07 ± 2.06	< 0.001

Bold values indicate significance ( P < 0.05)

For the Hardy–Weinberg equilibrium, no significant deviation from the expected population genotype proportions was detected at the MTHFR C677T (χ ² = 2.41, P = 0.12), MTHFR A1298C (χ ² = 3.65, P = 0.06), and MTRR A66G (χ ² = 3.42, P = 0.06).

Association of three missense mutations in MTHFR and MTRR genes and PCOS risk

Table 2 shows the genetic associations between the three MTHFR/MTRR mutations and PCOS in both univariable and multivariable additive, dominant, and recessive models. The MTHFR A1298C showed a significant association with PCOS under all the three models, and the association remained significant after adjusting for potential confounders and Bonferroni correction for multiple testing was applied ( P < 0.016). In the multivariable analysis of the additive model for MTHFR A1298C, a clear dose dependency was observed. Compared to the reference group (AA), those who carried one risk allele (AC) had 2.142 times higher risk of developing PCOS, and those who carried two risk alleles (CC) had 3.755 times higher risk. The MTRR A66G was nominally associated with PCOS (0.016 < p < 0.05) under the additive and recessive models, but not the dominant model. There was no association between MTHFR C677T and PCOS.

Table 2

Genotype distribution of MTHFR, MTRR mutations in the cases and controls according to additive, dominant, and recessive models

Gene & SNP	Model	Genotype	PCOS Group	Control Group	OR (95% CI)	P value	Adjusted OR ^a (95% CI)	P value
Gene & SNP	Model	Genotype	N (%)	N (%)	OR (95% CI)	P value	Adjusted OR ^a (95% CI)	P value
MTHFR C677T	Additive	CC	67 (44.7%)	157 (52.3%)	1	0.184	1	0.352
		CT	68 (45.3%)	109 (36.3%)	1.462 (0.964–2.217)		1.225 (0.790–1.899)
		TT	15 (10.0%)	34 (11.3%)	1.034 (0.528–2.023)		0.753 (0.372–1.524)
	Dominant	CT + TT	83 (55.3%)	143 (47.7%)	1	0.126	1	0.628
	Dominant	CC	67 (44.7%)	157 (52.3%)	0.735 (0.496–1.090)	0.126	0.902 (0.595–1.368)	0.628
	Recessive	TT	15 (10.0%)	34 (11.3%)	1	0.669	1	0.263
	Recessive	CC + CT	135 (90%)	266 (88.7%)	1.150 (0.605–2.186)	0.669	1.467 (0.750–2.870)	0.263
MTHFRA1298C	Additive	AA	65 (43.3%)	195 (65.0%)	1	< 0.001	1	< 0.001
		AC	63 (42.0%)	91 (30.3%)	2.077 (1.356–3.182)		2.142 (1.376–3.336)
		CC	22 (14.7%)	14 (4.7%)	4.714 (2.280–9.748)		3.755 (1.741–8.096)
	Dominant	AC + CC	85 (56.7%)	105 (35.0%)	1	< 0.001	1	< 0.001
	Dominant	AA	65 (43.3%)	195 (65.0%)	0.412 (0.276–0.615)	< 0.001	0.422 (0.277–0.641)	< 0.001
	Recessive	CC	22 (14.7%)	14 (4.7%)	1	< 0.001	1	0.008
	Recessive	AA + AC	128 (85.3%)	286 (95.3%)	0.285 (0.141–0.575)	< 0.001	0.368 (0.176–0.771)	0.008
MTRR A66G	Additive	AA	82 (54.7%)	162 (54.0%)	1	0.014	1	0.028
		AG	46 (30.7%)	118 (39.3%)	0.770 (0.500–1.186)		0.694 (0.442–1.088)
		GG	22 (14.7%)	20 (6.7%)	2.173 (1.122–4.210)		1.796 (0.902–3.572)
	Dominant	AG + GG	68 (45.3%)	138 (46.0%)	1	0.894	1	0.475
	Dominant	AA	82 (54.7%)	162 (54.0%)	1.027 (0.693–1.523)	0.894	1.162 (0.770–1.753)	0.475
	Recessive	GG	22 (14.7%)	20 (6.7%)	1	0.007	1	0.031
	Recessive	AA + AG	128 (85.3%)	280 (93.3%)	0.416 (0.219–0.789)	0.007	0.481 (0.247–0.935)	0.031

OR odds ratio, CI confidence intervals

^a Adjusted for potential confounders, including age, body mass index, folate, history of smoking, drinking, and hypertensive family history

Bold values indicate significance after Bonferroni correction for multiple comparisons ( P < 0.016, namely 0.05/3 for three SNPs)

After removing obese women from both studied groups, we found similar results (data not shown).

Association of three missense mutations in MTHFR and MTRR genes and serum homocysteine level

Table 3 shows associations between the three MTHFR/MTRR mutations and the serum homocysteine level for all participants after adjusting for potential confounders. Mutations in MTHFR A1298C and MTRR A66G were significantly associated with the serum homocysteine level. Participants having more risk alleles had a significant positive association with higher serum homocysteine levels than those with less. For example, compared to people who had no risk allele (AA), those who had one risk allele (AC) in MTHFR A1298C was 0.867 µmol/L higher in the homocysteine level, and two risk alleles (CC) was 2.092 µmol/L higher.

Table 3

Association of the three MTHFR/MTRR mutations and homocysteine levels

	Genotype	β ^a (95% CI)	P value
MTHFR C677T	CC	reference
	CT	0.034 (-0.124–0.193)	0.672
	TT	0.025 (-0.141–0.192)	0.764
MTHFR A1298C	AA	reference
	AC	0.867 (0.577–1.158)	< 0.001
	CC	2.092 (1.574–2.611)	< 0.001
MTRR A66G	AA	reference
	AG	-0.189 (-0.499–0.122)	0.233
	GG	0.704 (0.189–1.219)	0.007

^a Adjusted for potential confounders, including age, body mass index, folate, history of smoking, drinking, and hypertensive family history

Bold values indicate significance ( P < 0.05)

Mediation analysis

Table 4 shows whether the associations between three MTHFR/MTRR mutations and PCOS were mediated via homocysteine levels. The casual mediation analysis indicated that the effect of MTHFR A1298C on PCOS was mediated via the homocysteine level (indirect effect = 0.772 for AC; 1.861 for CC; p < 0.05 for both). For MTRR A66G, only the effect of the phenotype GG on PCOS was mediated via the homocysteine level (indirect effect = 0.623; p < 0.05). For both the MTHFR A1298C and MTRR A66G, no significant direct effect was observed. There was no direct or indirect association between MTHFR C677T and homocysteine level on PCOS.

Table 4

Mediation analysis of associations between three MTHFR/MTRR mutations and PCOS risk (mediated by homocysteine)

		Relative indirect effect (95% CI)	Relative direct effect (95% CI)	Total effect (95% CI)
MTHFR C677T	CC	reference	reference	-0.003 [-0.004 - (-0.002)]
	CT	0.062 (-0.240–0.354)	0.167 (-0.337–0.670)
	TT	0.069 (-0.492–0.706)	-0.431 (-1.260–0.399)
MTHFR A1298C	AA	reference	reference	0.102 (0.052–0.168)
	AC	0.772 (0.464–1.132)	0.155 (-0.353–0.663)
	CC	1.861 (1.085–2.777)	-0.054 (-1.092–0.985)
MTRR A66G	AA	reference	reference	0.014 (-0.001–0.036)
	AG	-0.169 (-0.473–0.115)	-0.344 (-0.855–0.166)
	GG	0.630 (0.149–1.211)	0.135 (-0.693–0.963)

All estimates obtained was adjusted for potential confounders, including age, body mass index, folate, history of smoking, drinking, and hypertensive family history, and used causal mediation analysis with SPSS’s Process command

Relative Direct effects: independent effects of three missense mutations on PCOS risk. Relative Indirect effects: effects of three missense mutations on PCOS risk (mediated by homocysteine)

Bold values indicate significance ( P < 0.05)

Discussion

Studies showed that an elevated homocysteine level may be related to the pathogenesis of PCOS. In this case-control study, we found that two mutations in homocysteine-related genes, namely MTHFR A1298C and MTRR A66G, were associated with the risk of PCOS, and the associations were mediated through influencing the level of homocysteine.

In our study, MTHFR A1298C was highly associated with PCOS after adjusting for potential confounders. Compared to the wild-type genotype AA, mutant homozygote genotype AC had a 2.142 times higher risk of PCOS, and CC had 3.755 times higher risk of PCOS, which showed that the effect size was stronger for each additional risk allele C. In agreement with our study, a recent meta-analysis demonstrated that MTHFR A1298C was associated with PCOS susceptibility [ 31]. For MTRR A66G, our results suggest an association with PCOS, but no significant association was found after multiple tests. A case-control study with 203 Brazilian participants showed that the polymorphic homozygous mutation of MTRR A66G was associated with protective factors for PCOS [ 32]. For the MTHFR C677T, we did not observe an association with PCOS; conflicting results have been reported, ranging from no observed association Poland [ 33] to the T allele being a risk factor for PCOS in the Korean population [ 34]. Such different conclusions of studies may be due to genetic mutations, race, region, and other factors, or due to differences in sample size.

Importantly, we also found that the association between MTHFR A1298C and PCOS was mediated by the serum homocysteine level. Mediation analysis examines what proportion of the SNP-PCOS association travels through homocysteine and acknowledges the fraction of the association that is independent of homocysteine. The result of the mediation analysis showed that the effect of A1298C on PCOS was through homocysteine. To our knowledge, this is the first study examining the potential mechanism underlying the association between genetic factors and the risk of PCOS. In addition, there is a biologically expected direction for the effect of A1298C on homocysteine and PCOS, in that A1298C with more risk alleles increased homocysteine levels and the risk of PCOS, which supports the mediation analysis results.

Homocysteine is a protein that is synthesized in the body and, ideally, is in low concentrations in the blood [ 35]. Elevated homocysteine is a risk factor for many diseases, including PCOS and cardiovascular disease [ 36– 41]. Therefore, our finding of the association between the homocysteine-related mutations and PCOS supports previous studies. However, to confirm the causality of the homocysteine levels and PCOS, a mendelian randomization study is needed. As the mutations of A1298C affect the function of MTHFR, drugs that treat MTHFR may reduce the risk of PCOS. Furthermore, as people with PCOS have a higher risk of cardiovascular disease, there may be an assumption that PCOS patients with a MTHFR A1298C AC/CC genotype may be prone to cardiovascular disease [ 42]. A key strength of this study is that we used mediation analysis to explain the biological rationality of the association between the risk mutations and PCOS. Furthermore, potential confounders were taken into account in the regression analyses.

However, several study limitations exist. Similar to other case-control studies, our study has limited verification of causality, but with the observations of other epidemiological supports from the Bradford-Hill Criteria [ 43], such as the temporal relation between the genes and PCOS outcome, the strong magnitude of effect, clear allele dose dependency, and biological plausibility, our findings increased the possibility of causality. Although the percentage of overweight or obesity in PCOS group is significantly higher than the control group (11.3% vs. 5.7%), there might be some inclusion bias since the pooled estimated prevalence of overweight and obesity in people with PCOS was 61% [ 30]. Another limitation is that we used convenience samples to examine the relationship between the risk alleles and homocysteine level, which prevented control of the representativeness of the samples. This lack of control may cause biased samples and research results, and thus limit the wider application of the study. In addition, as the association between the three mutations with PCOS may be ethnic-specific and the interactions between genes and the environment may also modulate PCOS risk, the findings of the present study need to be verified in different populations and other larger cohort studies.

In conclusion, MTHFR A1298C and MTRR A66G were associated with PCOS, and MTHFR A1298C might affect the risk of PCOS by influencing the homocysteine level. Drugs that treat MTHFR may reduce the risk of PCOS for people with the MTHFR A1298C AC/CC genotype.

Acknowledgements

We would like to thanks for the technical support provided by SurExam Bio-Tech Co., Ltd, Guangzhou, PR China and also for all the friends who helped, supported and encouraged me, especially Miss. Yuan Feilan.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Zhujiang Hospital, Southern Medical University and has been performed in accordance with the principles of Declaration of Helsinki. Written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

TREA Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. CrossRef

Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321–36. PubMedCrossRef

Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92. PubMedPubMedCentralCrossRef

Nardo LG, Patchava S, Laing I. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med. 2008;50(4):267. PubMed

Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol. 2009;26(4):281–96. CrossRef

Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Design. 2012;18(3):270. CrossRef

Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30(1):19–26. PubMedCrossRef

Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril. 2016;106(4):948–58. PubMedCrossRef

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487–525. PubMedPubMedCentralCrossRef

10.

Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril. 2016;106(1):16–24. PubMedCrossRef

11.

Azziz R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. Nat Rev Endocrinol. 2016;12(3):183. PubMedCrossRef

12.

Day F, Karaderi T, Drong RM, Kraft A, Lin P, Huang N, Broer H, Magi L, Saxena R, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLos Genet. 2018;14(12):e1007813. PubMedPubMedCentralCrossRef

13.

Hiam M-A, Laven T. The genetics of polycystic ovary syndrome: an overview of candidate gene systematic reviews and genome-wide association studies. J Clin Med. 2019;8(10):1606. PubMedCentralCrossRefPubMed

14.

Ruth KS, Beaumont RN, Tyrrell J, Jones SE, Tuke MA, Yaghootkar H, Wood AR, Freathy RM, Weedon MN, Frayling TM, et al. Genetic evidence that lower circulating FSH levels lengthen menstrual cycle, increase age at menopause and impact female reproductive health. Hum Reprod. 2016;31(2):473–81. PubMedPubMedCentralCrossRef

15.

Jones MR, Brower MA, Xu N, Cui J, Mengesha E, Chen YD, Taylor KD, Azziz R, Goodarzi MO. Systems genetics reveals the functional context of PCOS loci and identifies genetic and molecular mechanisms of disease heterogeneity. PLoS Genet. 2015;11(8):e1005455. PubMedPubMedCentralCrossRef

16.

Chang H, Xie L, Ge H, Wu Q, Wen Y, Zhang D, Zhang Y, Ma H, Gao J, Wang CC, et al. Effects of hyperhomocysteinaemia and metabolic syndrome on reproduction in women with polycystic ovary syndrome: a secondary analysis. Reprod Biomed Online. 2019;38(6):990–8. PubMedCrossRefPubMedCentral

17.

Li D, Liu H, Fang Y, Huo J, Wu Q, Wang T, Zhou Y, Wang X, Ma X. Hyperhomocysteinemia in polycystic ovary syndrome: decreased betaine-homocysteine methyltransferase and cystathionine β-synthase-mediated homocysteine metabolism. Reprod Biomed Online. 2018;37(2):234–41. PubMedCrossRefPubMedCentral

18.

Diwaker A, Kishore D. Evaluation of plasma homocysteine levels in patients of PCOS. J Assoc Physicians India. 2018;66(10):17–20. PubMed

19.

Fouani FZ, Fadaei R, Moradi N, Zandieh Z, Ansaripour S, Yekaninejad MS, Vatannejad A, Mahmoudi M. Circulating levels of Meteorin-like protein in polycystic ovary syndrome: a case-control study. PLOS ONE. 2020;15(4):e231943. CrossRef

20.

Qi X, Zhang B, Zhao Y, Li R, Chang HM, Pang Y, Qiao J. Hyperhomocysteinemia promotes insulin resistance and adipose tissue inflammation in PCOS mice through modulating M2 macrophage polarization via estrogen suppression. Endocrinology. 2017;158(5):1181–93. PubMedCrossRef

21.

Portillo F, Vázquez J, Pajares MA. Protein-protein interactions involving enzymes of the mammalian methionine and homocysteine metabolism. Biochimie. 2020;173:33–47. PubMedCrossRef

22.

Forges T, Chery C, Audonnet S, Feillet F, Gueant J. Life-threatening methylenetetrahydrofolate reductase (MTHFR) deficiency with extremely early onset: Characterization of two novel mutations in compound heterozygous patients. Mol Genet Metab. 2010;100(2):143–8. PubMedCrossRef

23.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111. PubMedCrossRef

24.

Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, Breteler MM, Bautista LE, Sharma P, Whittaker JC, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. The Lancet. 2011;378(9791):584–94. CrossRef

25.

Watkins D, Rosenblatt DS. Update and new concepts in vitamin responsive disorders of folate transport and metabolism. J Inherit Metab Dis. 2012;35(4):665–70. PubMedCrossRef

26.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64(3):169–72. PubMedCrossRef

27.

Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase†. Biochemistry-Us. 2002;41(45):13378–85. CrossRef

28.

TREA Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. CrossRef

29.

Yuan Y, Li J, Jing Z, Yu C, Zhao D, Hao W, Zhou C. The role of mental health and physical activity in the association between sleep quality and quality of life among rural elderly in China: a moderated mediation model. J Affect Disorders. 2020;273:462–7. PubMedCrossRef

30.

Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618–37. PubMedCrossRef

31.

Zhu X, Hong X, Chen L, Xuan Y, Huang K, Wang B. Association of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms with genetic susceptibility to polycystic ovary syndrome: a PRISMA-compliant meta-analysis. Gene. 2019;719:144079. PubMedCrossRef

32.

Santos TBD, Paula HKD, Balarin MAS, Silva-Grecco RL, Lima MFP, Resende EAMR, Gomes MKO, Cintra MTR. Can the genetic polymorphisms of the folate metabolism have an influence in the polycystic ovary syndrome? Arch Endocrinol Metab. 2019;63:501–8. PubMed

33.

Szafarowska M, Segiet A, Jerzak MM. Methylenotetrahydrololate reductase A1298C and C677T polymorphisms and adverse pregnancy outcome in women with PCOS. Neuro Endocrinol Lett. 2016;37(2):141. PubMed

34.

Ożegowska K, Bogacz A, Bartkowiak-Wieczorek J, Seremak-Mrozikiewicz A, Pawelczyk L. Is there an association between the development of metabolic syndrome in PCOS patients and the C677T MTHFR gene polymorphism? Ginekol Pol. 2016;87(4):246. PubMedCrossRef

35.

Finkelstein JD, Martin JJ. Homocysteine. Int J Biochem Cell Biol. 2000;32(4):385–9. PubMedCrossRef

36.

Kozakova M, Morizzo C, Penno G, Shore AC, Nilsson J, Palombo C. Plasma homocysteine and cardiovascular organ damage in a population with a high prevalence of risk factors. J Clin Endocrinol Metab. 2020;105(8).

37.

Mondal K, Chakraborty P, Kabir SN. Hyperhomocysteinemia and hyperandrogenemia share PCSK9-LDLR pathway to disrupt lipid homeostasis in PCOS. Biochem Biophys Res Commun. 2018;503(1):8–13. PubMedCrossRef

38.

Akhtar N. Is homocysteine a risk factor for atherothrombotic cardiovascular disease? J Am Coll Cardiol. 2007;49(12):1370–1. PubMedCrossRef

39.

Schiuma N, Costantino A, Bartolotti T, Dattilo M, Bini V, Aglietti MC, Renga M, Favilli A, Falorni A, Gerli S. Micronutrients in support to the one carbon cycle for the modulation of blood fasting homocysteine in PCOS women. J Endocrinol Invest. 2020;43(6):779–86. PubMedCrossRef

40.

Yilmaz N, Pektas M, Tonguc E, Kilic S, Gulerman C, Gungor T, Mollamahmutoglu L. The correlation of plasma homocysteine with insulin resistance in polycystic ovary syndrome. J Obstet Gynaecol Res. 2008;34(3):384–91. PubMedCrossRef

41.

Wu Y, Huang Y, Hu Y, Zhong J, He Z, Li W, Yang Y, Xu D, Wu S. Hyperhomocysteinemia is an independent risk factor in young patients with coronary artery disease in southern China. Herz. 2013;38(7):779–84. PubMedCrossRef

42.

Yaralı H, Yıldırır A, Aybar F, Kabakçı G, Bükülmez O, Akgül E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertili Sterili. 2001;76(3):511–6. CrossRef

43.

Cox LA. Modernizing the Bradford Hill criteria for assessing causal relationships in observational data. Crit Rev Toxicol. 2018;48(8):682–712. PubMedCrossRef

Titel: Association of three missense mutations in the homocysteine-related MTHFR and MTRR gene with risk of polycystic ovary syndrome in Southern Chinese women
Autoren:: Wanqin Feng
Yan Zhang
Yuan Pan
Yi Zhang
Minjuan Liu
Yuxin Huang
Yuanling Xiao
Wenyu Mo
Junjie Jiao
Xiaoyang Wang
Dan Tian
Lixia Yang
Ying Ma
Publikationsdatum: 01.12.2021
DOI: https://doi.org/10.1186/s12958-020-00688-8
Verlag: BioMed Central
Zeitschrift: Reproductive Biology and Endocrinology
Ausgabe 1/2021
Elektronische ISSN: 1477-7827

Neu im Fachgebiet Gynäkologie und Geburtshilfe

03.03.2021 | Mammakarzinom | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

Association of three missense mutations in the homocysteine-related MTHFR and MTRR gene with risk of polycystic ovary syndrome in Southern Chinese women

Publisher’s Note

Background

Materials and methods

Participants

Measures

Serum measurements

DNA extraction and genotyping

Statistical analysis

Results

Participant characteristics

Association of three missense mutations in MTHFR and MTRR genes and PCOS risk

Association of three missense mutations in MTHFR and MTRR genes and serum homocysteine level

Mediation analysis

Discussion

Acknowledgements

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Frauen mit krebskranken Verwandten früher screenen?

Nach chirurgischer Menopause steigt das Depressionsrisiko

So gefährlich sind schwere COVID-19-Verläufe in der Schwangerschaft!

Verdächtiger Mammografie-Befund? Covid-19-Impfung!

Newsletter

Springer Medizin

Publisher’s Note

Background

Materials and methods

Participants

Measures

Serum measurements

DNA extraction and genotyping

Statistical analysis

Results

Participant characteristics

Association of three missense mutations in MTHFR and MTRR genes and PCOS risk

Association of three missense mutations in MTHFR and MTRR genes and serum homocysteine level

Mediation analysis

Discussion

Acknowledgements

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Weitere Artikel der Ausgabe 1/2021

Patients with IVF complicated by moderate-to-critical OHSS experience increased thrombosis, GDM and neonatal NICU admission but slightly shorter gestation compared with matched IVF counterparts: A retrospective Chinese cohort study

The LINC00477/miR-128 axis promotes the progression of polycystic ovary syndrome by regulating ovarian granulosa cell proliferation and apoptosis

Silencing of MEG3 attenuated the role of lipopolysaccharides by modulating the miR-93-5p/PTEN pathway in Leydig cells

Novel variants in DNAH9 lead to nonsyndromic severe asthenozoospermia

Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis

Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Frauen mit krebskranken Verwandten früher screenen?

Nach chirurgischer Menopause steigt das Depressionsrisiko

So gefährlich sind schwere COVID-19-Verläufe in der Schwangerschaft!

Verdächtiger Mammografie-Befund? Covid-19-Impfung!

Newsletter